Full Text View
Tabular View
No Study Results Posted
Related Studies
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
This study has been completed.
Study NCT00053612   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: February 3, 2003   Last Updated: September 17, 2007   History of Changes

February 3, 2003
September 17, 2007
 
 
 
 
Complete list of historical versions of study NCT00053612 on ClinicalTrials.gov Archive Site
 
 
 
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Prevention of HIV Shedding in Women - Trial of Vitamin A

HIV infected individuals with vitamin A deficiency may be more likely to transmit the virus to others than HIV infected individuals who have normal levels of vitamin A. The presence of HIV DNA in vaginal secretions may indicate a greater risk for transmission of HIV to others. The purpose of this study is to determine if taking vitamin A decreases the level of HIV DNA in vaginal secretions.

Vitamin A deficiency leads to pathological changes in mucosal epithelium, including the vagina, and is correlated with immune dysfunction in both HIV-1 infected and uninfected individuals. Recent studies of genital tract shedding of HIV-1 DNA in infected women have found that lower serum concentrations of vitamin A were strongly associated with detection of HIV-1 in vaginal secretions. In addition, maternal vitamin A deficiency has been associated with significantly increased risk of vertical HIV-1 transmission. This study will assess the effect of vitamin A supplementation on the prevalence and quantity of HIV-1 DNA and RNA in cervical and vaginal secretions.

Participants in this study will be HIV infected nonpregnant women in Mombasa, Kenya. Participants will be randomized to receive 6 weeks of daily dosage of either 10,000 IU vitamin A or placebo. Cervical and vaginal swabs will be obtained at enrollment and at Week 6 for detection and quantification of HIV-1 DNA and RNA. In addition, venous blood will be obtained at the two time points for quantification of plasma HIV-1 RNA, CD4 lymphocyte count, and serum vitamin A levels.

Phase II
Interventional
Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
  • HIV Infections
  • Vitamin A Deficiency
  • HIV Seronegativity
Drug: Vitamin A
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
400
 
 

Inclusion Criteria:

  • HIV infected

Exlusion Criteria:

  • Pregnant
Female
 
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00053612
 
R01AI343844, R01-AI343844
National Institute of Allergy and Infectious Diseases (NIAID)
 
Principal Investigator: Joan Kreiss, MD, MPH Universiy of Washington, Seattle, WA
National Institute of Allergy and Infectious Diseases (NIAID)
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP